Abstract. Osteopontin, a key structural protein in the extracellular matrix, plays a pivotal role in regulating the local tumor microenvironment and systemic immunity during cancer progression. Recognizing that tumor cells do not exist in isolation but rather interact with a multitude of stromal components that significantly influence patient outcomes and therapy responses, this review focuses on the role of osteopontin in non-tumor cells in the context of solid cancers and the associated phenotypic and mechanistic insights. We explore how osteopontin influences the behavior of various innate and adaptive immune cells, including natural killer cells, neutrophils, macrophages, dendritic cells, myeloid-derived suppressor cells, B cells, T cells, as well as structural stromal cells such as fibroblasts, endothelial cells, and adipocytes. The review highlights the roles of osteopontin in modulating these stromal cells and their multiaxial influence on tumorigenesis and metastasis. These complex interplays offer insights into potential diagnostic and therapeutic strategies around osteopontin/stromal-mediated pathways in cancer progression and recurrence.

Abstract. Osteopontin, a key structural protein in the extracellular matrix, plays a pivotal role in regulating the local tumor microenvironment and systemic immunity during cancer progression. Recognizing that tumor cells do not exist in isolation but rather interact with a multitude of stromal components that significantly influence patient outcomes and therapy responses, this review focuses on the role of osteopontin in non-tumor cells in the context of solid cancers and the associated phenotypic and mechanistic insights. We explore how osteopontin influences the behavior of various innate and adaptive immune cells, including natural killer cells, neutrophils, macrophages, dendritic cells, myeloid-derived suppressor cells, B cells, T cells, as well as structural stromal cells such as fibroblasts, endothelial cells, and adipocytes. The review highlights the roles of osteopontin in modulating these stromal cells and their multiaxial influence on tumorigenesis and metastasis. These complex interplays offer insights into potential diagnostic and therapeutic strategies around osteopontin/stromal-mediated pathways in cancer progression and recurrence.

The MET receptor tyrosine kinase is a pivotal regulator of cellular survival, motility, and proliferation. Mutations leading to skipping of exon 14 (METΔex14) within the juxtamembrane domain of MET im...

Une nouvelle étude menée par Hannah Garner, Ph.D., nouvellement chercheuse à l’Institut du cancer Rosalind et Morris Goodman (ICG), publiée dans le journal Cancer Cell, a montré que les cellules...

A recent study from Hannah Garner, Ph.D. and new member of the Rosalind and Morris Goodman Cancer Institute (GCI), published in Cancer Cell, showed that neutrophil precursors located in the bone marrow receive signals from mammary tumours and promote metastasis.

Le 25 avril marque la Journée de l’ADN, une occasion de souligner les publications marquantes sur la structure de l’ADN et une célébration des accomplissements de la recherche en génétique. Les progrès de la recherche sur l’ADN et la génomique ont révolutionné notre compréhension du cancer, menant à des améliorations significatives pour la détection, le suivi et le traitement du cancer. À l’Institut du cancer Rosalind et Morris Goodman (ICG), nos chercheurs et chercheuses sont à la pointe de la biologie du génome du cancer.